Last updated: September 2, 2026
Trifluridine/tipiracil hydrochloride, marketed as Lonsurf by Taiho Pharmaceutical and Taiho Oncology, is an oral antimetabolite combination for previously treated metastatic colorectal cancer and metastatic gastric or gastroesophageal-junction adenocarcinoma. Its commercial position strengthened materially after the FDA authorized Lonsurf plus bevacizumab for metastatic colorectal cancer in 2023.
The product has moved from a late-line niche therapy to a larger oncology franchise supported by combination treatment, global expansion and increasing use after standard chemotherapy, anti-VEGF therapy and anti-EGFR therapy. The principal medium-term risks are oral generic entry, price pressure from competing late-line agents and dependence on the colorectal cancer market.
What is trifluridine/tipiracil hydrochloride and how does Lonsurf work?
Lonsurf combines trifluridine, a thymidine-based nucleoside analogue, with tipiracil hydrochloride, a thymidine phosphorylase inhibitor. Tipiracil increases systemic exposure to trifluridine by reducing its rapid degradation.
| Attribute |
Product detail |
| Brand |
Lonsurf |
| Active ingredients |
Trifluridine and tipiracil hydrochloride |
| Dosage form |
Oral tablets |
| Original U.S. approval |
September 22, 2015 |
| Initial indication |
Previously treated metastatic colorectal cancer |
| Additional U.S. indication |
Metastatic gastric or gastroesophageal-junction adenocarcinoma, 2019 |
| Combination expansion |
Lonsurf plus bevacizumab for metastatic colorectal cancer, 2023 |
| Primary manufacturers |
Taiho Pharmaceutical, Taiho Oncology |
| Parent company |
Otsuka Holdings |
| Therapeutic category |
Antineoplastic, oral cytotoxic therapy |
The standard monotherapy regimen is based on body-surface area and is administered twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle. The principal dose-limiting toxicities are neutropenia, anemia, thrombocytopenia, fatigue, nausea and diarrhea. The bevacizumab combination adds hypertension, proteinuria, bleeding and thromboembolic monitoring requirements.[1]
What FDA approvals support the Lonsurf market?
Lonsurf has three commercially relevant U.S. approval milestones.
| Date |
FDA milestone |
Commercial effect |
| September 2015 |
Approval for metastatic colorectal cancer after fluoropyrimidine-, oxaliplatin- and irinotecan-based therapy, with prior anti-VEGF and anti-EGFR treatment where appropriate |
Established the initial late-line market |
| February 2019 |
Approval for metastatic gastric or gastroesophageal-junction adenocarcinoma after at least two prior lines |
Added a second tumor type |
| August 2023 |
Approval with bevacizumab for metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologic therapy |
Expanded clinical use and improved treatment efficacy |
The 2023 approval was commercially important because the combination produced a median overall survival of 10.8 months versus 7.5 months for Lonsurf alone in the SUNLIGHT study. Progression-free survival was 5.6 months versus 2.4 months.[2] The combination also gives Taiho a differentiated treatment position against oral multikinase inhibitors and other late-line therapies.
How large is the trifluridine/tipiracil market?
The addressable market is concentrated in previously treated metastatic colorectal cancer. Gastric cancer contributes a smaller but strategically important share.
Key market drivers include:
- Longer survival among patients who reach third-line and later treatment.
- Increasing use of biomarker-directed therapy earlier in the treatment sequence, leaving a larger population for later-line treatment.
- The 2023 Lonsurf-bevacizumab label expansion.
- Global commercialization through Otsuka and regional partners.
- Oral administration, which supports outpatient use and reduces infusion burden.
- Activity across colorectal cancer subgroups, including patients with refractory disease.
The product competes directly with regorafenib, fruquintinib and, in some markets, best supportive care. It also competes indirectly with newer biomarker-defined therapies, including agents directed at BRAF V600E, HER2, KRAS G12C and mismatch-repair or microsatellite-instability status.
How does Lonsurf compare with regorafenib and fruquintinib?
| Factor |
Lonsurf |
Regorafenib |
Fruquintinib |
| Drug type |
Oral cytotoxic combination |
Oral multikinase inhibitor |
Oral VEGFR inhibitor |
| Main use |
Refractory metastatic colorectal cancer; gastric/GEJ cancer |
Refractory metastatic colorectal cancer and selected gastrointestinal cancers |
Previously treated metastatic colorectal cancer |
| Key toxicity profile |
Myelosuppression and gastrointestinal toxicity |
Hand-foot syndrome, fatigue, hypertension, hepatotoxicity |
Hypertension, hand-foot syndrome, proteinuria |
| Combination opportunity |
Bevacizumab combination approved in U.S. |
Combination development ongoing across settings |
Primarily monotherapy commercial positioning |
| Generic or follow-on risk |
Conventional generic risk |
Conventional generic risk |
Conventional generic risk |
| Differentiation |
Survival benefit with bevacizumab and established global use |
Earlier market entry and broad kinase activity |
VEGFR selectivity and newer launch profile |
Lonsurf's strongest competitive advantage is the SUNLIGHT-supported combination with bevacizumab. Its principal weakness is hematologic toxicity, which can require treatment interruption, dose reduction or growth-factor support.
What patents protect trifluridine/tipiracil hydrochloride?
The U.S. Orange Book lists Lonsurf patents covering the trifluridine/tipiracil pharmaceutical combination and related methods of use. The relevant patent estate is more important for generic entry than for biosimilar competition because Lonsurf is a small-molecule drug, not a biologic.[3]
The estate can be divided into four technical categories:
| Patent category |
Protected subject matter |
Commercial relevance |
| Composition patents |
The combination of trifluridine and tipiracil, including pharmaceutical ratios and compositions |
Core protection for the tablet product |
| Dosing patents |
Administration schedules, dose levels and treatment cycles |
Can complicate ANDA label design |
| Method-of-use patents |
Treatment of colorectal, gastric and related cancers |
Relevant to Paragraph IV litigation and skinny-label strategies |
| Combination-treatment patents |
Use with bevacizumab and other anticancer therapies |
Supports the post-2023 franchise |
The earliest core U.S. patent protection is generally associated with the late-2020s rather than the original 2020 regulatory exclusivity expiry. Orange Book-listed patents, patent-term adjustments and any pediatric extension determine the practical U.S. launch boundary for an ANDA applicant.
Patent protection is jurisdiction-specific. Japan, the United States, Europe and other markets have different patent families, term adjustments, supplementary protection certificates and litigation outcomes. The United States is the most commercially significant jurisdiction because of the size of the colorectal cancer market and the ability of an ANDA applicant to challenge listed patents.
When does Lonsurf lose exclusivity?
Lonsurf's regulatory exclusivity has largely expired, but patent protection remains the principal barrier to generic entry.
| Exclusivity type |
Timing and effect |
| New chemical entity exclusivity |
The original five-year period ran from the 2015 U.S. approval and expired in 2020 |
| New clinical investigation exclusivity |
The 2019 gastric-cancer indication received indication-specific protection that extended into the early 2020s |
| Bevacizumab combination indication |
The 2023 supplement created a separate period of regulatory protection for the qualifying clinical investigation |
| Patent exclusivity |
Continues beyond regulatory exclusivity and controls the principal generic-launch risk |
| Pediatric exclusivity |
Any applicable six-month extension must be confirmed against the current Orange Book entry and patent term |
Regulatory exclusivity does not prevent an ANDA filing once the statutory filing window opens. Patent certifications, Paragraph IV notices and litigation determine whether a generic can launch before the relevant patent expiry.
Are there Paragraph IV challenges to Lonsurf?
A Paragraph IV challenge would assert that one or more Orange Book-listed patents are invalid, unenforceable or not infringed. The challenge would normally be filed through an ANDA seeking approval for a generic trifluridine/tipiracil tablet.
The key litigation issues are likely to include:
- Whether the claimed trifluridine-to-tipiracil ratio is novel and non-obvious.
- Whether the claimed dosage schedule is patentable over prior clinical and pharmacology disclosures.
- Whether a generic label induces infringement of method-of-use claims.
- Whether a generic can omit the gastric-cancer or bevacizumab-related indication through a section viii statement or a restricted label.
- Whether formulation differences avoid composition or pharmaceutical-composition claims.
The first filer could receive 180-day generic exclusivity if it qualifies under the applicable ANDA rules. A successful first-filer challenge could therefore create a temporary market structure with one authorized or approved generic before broader competition.
Public patent litigation and FDA listing data should be evaluated together. A patent may remain listed while a court settlement, covenant not to sue, license or launch authorization materially changes the commercial outcome.
What generic launch risks exist for Lonsurf?
Lonsurf faces conventional generic risk rather than biosimilar risk. Generic manufacturers can pursue an ANDA by demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug.
High-risk launch scenario
A generic manufacturer obtains approval after prevailing in Paragraph IV litigation or reaching a license that permits an early launch. Multiple manufacturers then enter after the first-filer period or patent expiry. U.S. net pricing declines, and Taiho's revenue shifts toward the bevacizumab combination and non-U.S. markets.
Moderate-risk launch scenario
One or two generic manufacturers enter under a settlement date before full patent expiry. The generic label excludes one or more protected indications. Lonsurf retains use in the protected combination or method-of-use segment, while monotherapy pricing declines.
Lower-risk launch scenario
Patents withstand validity and infringement challenges, or settlements delay generic entry until the late 2020s. Taiho uses the remaining period to convert patients to Lonsurf plus bevacizumab and expand use in gastric cancer and international markets.
The most important commercial distinction is whether generic products can carry the full colorectal cancer indication and whether the Lonsurf-bevacizumab regimen is separately protected. A narrow generic label would reduce immediate substitution but would not eliminate pharmacy or payer pressure.
Does trifluridine/tipiracil face biosimilar competition?
No. Lonsurf is a small-molecule tablet and is subject to the generic-drug pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Biosimilar competition under section 351(k) applies to biologic products, not to trifluridine/tipiracil tablets.
The relevant follow-on risks are:
- ANDA approvals.
- Authorized generic introduction by the originator or a partner.
- Off-label substitution pressure.
- Formulary-driven switching.
- International generic launches after local patent expiry.
- Price reductions in government and managed-care channels.
What is the financial trajectory for Lonsurf?
Lonsurf's financial trajectory has been driven by indication expansion rather than a single launch event. The product initially served a narrow refractory colorectal cancer population. The 2019 gastric indication broadened the base, while the 2023 bevacizumab approval increased treatment value per patient and improved the growth outlook.
Otsuka reports Lonsurf within its pharmaceutical business and has identified the product as a growth contributor. Public reporting generally provides product sales at the group or regional level rather than a complete global net-sales bridge by indication.[4]
| Period |
Financial trajectory |
| 2015-2018 |
Initial commercialization in refractory colorectal cancer |
| 2019-2022 |
Expansion into gastric and gastroesophageal-junction cancer |
| 2023-2025 |
Growth from the SUNLIGHT-based bevacizumab combination and broader colorectal cancer adoption |
| Late 2020s |
Increasing exposure to generic-entry risk as core patent terms approach expiry |
Revenue quality is relatively strong because Lonsurf is an established product with repeat-cycle use. The main limitations are treatment duration, dose reductions caused by neutropenia and dependence on late-line patient flow.
The 2023 combination approval also changes the product's economic profile. Bevacizumab can increase total regimen cost and support continued use in patients who might otherwise transition to regorafenib, fruquintinib or supportive care. The combination may therefore delay revenue erosion, even if monotherapy faces generic competition.
Which companies compete with or may challenge Lonsurf?
The competitive field includes pharmaceutical companies selling late-line colorectal cancer therapies and generic manufacturers capable of filing ANDAs.
| Company or product |
Competitive relevance |
| Bayer, Stivarga |
Established oral late-line colorectal cancer competitor |
| Takeda, Fruzaqla |
VEGFR-directed competitor in previously treated metastatic colorectal cancer |
| Taiho and Otsuka |
Originator and commercial owner of Lonsurf |
| Generic manufacturers |
Potential ANDA applicants after patent challenges or settlement agreements |
| Roche and other bevacizumab suppliers |
Important partners in the Lonsurf-bevacizumab treatment model |
Fruzaqla's U.S. launch added a newer oral competitor to the same broad late-line colorectal cancer population. Lonsurf retains a differentiated position through its cytotoxic mechanism, extensive clinical history and the approved bevacizumab combination.
What geographic markets protect Lonsurf?
Lonsurf has been commercialized across major oncology markets, including the United States, Japan and Europe, with regional regulatory and commercial arrangements. Patent expiry is not synchronized globally.
Geographic factors affecting revenue include:
- U.S. patent listings and ANDA litigation.
- European supplementary protection certificates and national validation.
- Japan's originator-market economics and Taiho's local position.
- Reimbursement decisions for the bevacizumab combination.
- Generic approval timing in China, South Korea and other Asian markets.
- Local compulsory licensing, patent-linkage and data-exclusivity rules.
The United States remains the highest-value patent and litigation jurisdiction. Japan is strategically important because Taiho has stronger commercial infrastructure there. Europe has a fragmented reimbursement and national patent environment, which can produce staggered generic entry.
How strong is the trifluridine/tipiracil patent estate?
The estate is commercially meaningful but not impenetrable.
Strengths include:
- A clinically validated combination with defined active-ingredient ratios.
- Multiple potential claim types covering composition, dosing and treatment methods.
- A differentiated combination regimen with bevacizumab.
- Significant commercial value that gives generic applicants an incentive to challenge.
Weaknesses include:
- The active ingredients and broad anticancer use have extensive prior-art exposure.
- Small-molecule composition claims face conventional obviousness and written-description attacks.
- Method-of-use claims may be avoided through restricted labeling.
- The original regulatory exclusivity period has ended.
- Generic manufacturers can target formulation and dosing claims separately.
The estate's practical strength depends less on the number of listed patents than on whether at least one enforceable patent blocks a commercially useful generic label through the late 2020s.
Key Takeaways
- Trifluridine/tipiracil hydrochloride is marketed as Lonsurf for refractory metastatic colorectal cancer and metastatic gastric or gastroesophageal-junction cancer.
- The 2023 FDA approval with bevacizumab is the main growth catalyst and the most important product-life-cycle expansion.
- Regulatory exclusivity has expired or is no longer the primary barrier; U.S. Orange Book-listed patents control generic timing.
- Lonsurf faces generic, not biosimilar, competition.
- The likely commercial battleground is whether an ANDA applicant can launch with a full colorectal cancer label or a restricted label that omits protected methods.
- Regorafenib and fruquintinib are the principal branded competitors.
- Taiho's financial exposure is concentrated in late-line colorectal cancer and increases as the product approaches late-2020s patent risk.
- The strongest defense is the Lonsurf-bevacizumab regimen, supported by the SUNLIGHT survival data and potential method-of-use protection.
FAQs about trifluridine/tipiracil hydrochloride
Is Lonsurf the same as TAS-102?
Yes. TAS-102 is the development code for the fixed-dose combination of trifluridine and tipiracil hydrochloride. Lonsurf is the commercial brand.
Is trifluridine/tipiracil chemotherapy?
Yes. Trifluridine/tipiracil is an oral cytotoxic antineoplastic therapy. It is pharmacologically distinct from fluoropyrimidine chemotherapy but is used in later-line treatment after standard fluoropyrimidine-based regimens.
Can Lonsurf be taken with bevacizumab?
Yes. The FDA approved Lonsurf plus bevacizumab for previously treated metastatic colorectal cancer in 2023. The combination has a different safety profile and requires monitoring for both myelosuppression and bevacizumab-related adverse events.
What is the main dose-limiting toxicity of Lonsurf?
Neutropenia is the principal dose-limiting toxicity. Anemia, thrombocytopenia, fatigue, nausea and diarrhea are also common and can lead to treatment interruptions or dose reductions.
Will generic trifluridine/tipiracil automatically substitute for Lonsurf?
An approved generic may be substitutable under state pharmacy laws and payer rules, but substitution depends on FDA therapeutic-equivalence ratings, the approved label, patent settlements and formulary policy. A generic with a restricted label may not have the same approved indications as Lonsurf.
References
-
U.S. Food and Drug Administration. (2024). Lonsurf (trifluridine and tipiracil) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/207981s011lbl.pdf
-
U.S. Food and Drug Administration. (2023, August 2). FDA approves trifluridine/tipiracil with bevacizumab for metastatic colorectal cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-trifluridinetipiracil-bevacizumab-metastatic-colorectal-cancer
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Otsuka Holdings Co., Ltd. (2024). Annual report and financial results materials. https://www.otsuka.com/en/ir/library/annual/
